Pharmacokinetics of Morphine and Its Metabolites in Infants and Young Children After Congenital Heart Surgery
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 1
Abstract
The objective of this study was to characterize morphine glucuronidation in infants and children following cardiac surgery for possible treatment individualization in this population. Twenty children aged 3 days to 6 years, admitted to the cardiovascular intensive care unit after congenital heart surgery, received an intravenous (IV) loading dose of morphine (0.15 mg/kg) followed by subsequent intermittent IV bolus doses based on a validated pain scale. Plasma samples were collected over 6 h after the loading dose and randomly after follow-up doses to measure morphine and its major metabolite concentrations. A population pharmacokinetic model was developed with the non-linear mixed effects software NONMEM. Parent disposition was adequately described by a linear two-compartment model. Effect of growth (size and maturation) on morphine parameters was accounted for by allometric body weight-based models. An intermediate compartment with Emax model best characterized glucuronide concentrations. Glomerular filtration rate was identified as a significant predictor of glucuronide formation time delay and maximum concentrations. Clearance of morphine in children with congenital heart disease is comparable to that reported in children without cardiac abnormalities of similar age. Children 1–6 months of age need higher morphine doses per kilogram to achieve an area under concentration–time curve comparable to that in older children. Pediatric patients with renal failure receiving morphine therapy are at increased risk of developing opioid toxicity due to accumulation of morphine metabolites.
Authors and Affiliations
Mohammed H. Elkomy, David R. Drover, Kristi L. Glotzbach, Jeffery L. Galinkin, Adam Frymoyer, Felice Su, Gregory B. Hammer
Keywords
Related Articles
- EP ID EP680823
- DOI 10.1208/s12248-015-9826-5
- Views 65
- Downloads 0
Measuring Endocannabinoid Hydrolysis: Refining our Tools and Understanding
Endocannabinoids (eCBs) are lipid transmitters that are released from membrane precursors in response to specific stimuli, activate cannabinoid receptors—the molecular targets of compounds produced by Cannabis sa...
Different Pharmaceutical Products Need Similar Terminology
The online version of this article (doi:10.1208/s12248-013-9532-0) contains supplementary material, which is available to authorized users.
Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein
An hPepT1-GFP fusion construct was made to study drug inhibition of dipeptide uptake and apical, basolateral, or subcellular hPepT1 localization. The hPepT1 stop codon was mutated by polymerase chain reaction and was sub...
First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry
Since the federal authorities scheduled the first synthetic cannabinoids, JWH-018 and JWH-073, new synthetic cannabinoids were robustly marketed. N-(1-Adamantyl)-1-pentylindazole-3-carboxamide (AKB-48), also known as API...
Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment
Arginine-rich cell-penetrating peptides (AR-CPPs) are very promising tools for the delivery of therapeutic macromolecules such as peptides, proteins, and nucleic acids. These peptides allow efficient internalization of t...